Rare copy number variants have been identified in a study of children who have growth hormone insensitivity or insulin-like growth factor-1 insensitivity, shedding light on the genetic basis of their conditions.
The C-type natriuretic peptide analogue vosoritide significantly increases the growth rate of children with achondroplasia, indicate the results of a randomised, double-blind phase 3 study published in The Lancet.
Following the publication of the long-term mortality findings of the SAGhE consortium, we discuss the safety profile of growth hormone with consortium member Stefano Cianfarani.
Receiving treatment with recombinant human growth hormone in childhood is unlikely to be associated with an increased risk for mortality in the long term, show the results of the full SAGhE cohort.
Thursday, November 5, 2020, 16:30 -18:00 (GMT) / 17:30 – 19:00 (CET) – Join our expert panel as they present evidence and discuss how digital solutions can help with the diagnosis and management of growth disorders.
Severe growth hormone deficiency can be detected with high accuracy using newborn screening cards, suggest researchers who recommend a diagnostic GH cutoff of less than 7 µg/L.
Three-week-old baby referred to the paediatric endocrine clinic from a general paediatrician with ambiguous genitalia, accompanied by very anxious and upset parents.
Childhood cancer survivors and endocrinopathies – the need for oncologist and endocrinologist collaboration
Dr Sogol Mostoufi focuses on the treatment-related endocrine side effects commonly experienced by childhood cancer survivors, and the need for screening, life-long follow-up and treatment in this high-risk population.
Click here to view the full on-demand webcast
Translational advances in the management of growth and puberty disorders
Recorded in São Paolo, Brazil
Register now t […]